CYP17 promoter variant associated with prostate cancer aggressiveness in African Americans

Rick A Kittles, R. K. Panguluri, W. Chen, A. Massac, C. Ahaghotu, A. Jackson, F. Ukoli, L. Adams-Campbell, W. Isaacs, G. M. Dunston

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Androgens play an important role in the etiology of prostate cancer. The CYP17 gene encodes the cytochrome P450c17α enzyme, which is the rate-limiting enzyme in androgen biosynthesis. A T to C polymorphism in the 5′ promoter region has recently been associated with prostate cancer. However, contradictory data exists concerning the risk allele. To investigate further the involvement of the CYP17 variant with prostate cancer, we typed the polymorphism in three different populations and evaluated its association with prostate cancer and clinical presentation in African Americans. We genotyped the CYP17 polymorphism in Nigerian (n = 56), European-American (n = 74), and African-American (n = 111) healthy male volunteers, along with African-American men affected with prostate cancer (n = 71), using pyrosequencing. Genotype and allele frequencies did not differ significantly across the different control populations. African-American men with the CC CYP17 genotype had an increased risk of prostate cancer (odds ratio, 2.8; 95% confidence interval, 1.0-7.4) compared with those with the TT genotype. A similar trend was observed between the homozygous variant genotype in African-American prostate cancer patients and clinical presentation. The CC genotype was significantly associated with higher grade and stage of prostate cancer (odds ratio, 7.1; 95% confidence interval, 1.4-36,1). The risk did not differ significantly by family history or age. Our results suggest that the C allele of the CYP17 polymorphism is significantly associated with increased prostate cancer risk and clinically advanced disease in African Americans.

Original languageEnglish (US)
Pages (from-to)943-947
Number of pages5
JournalCancer Epidemiology Biomarkers and Prevention
Volume10
Issue number9
StatePublished - 2001
Externally publishedYes

Fingerprint

Steroid 17-alpha-Hydroxylase
African Americans
Prostatic Neoplasms
Genotype
Androgens
Alleles
Odds Ratio
Confidence Intervals
Prostate Cancer, Hereditary, 7
Enzymes
Cytochromes
Genetic Promoter Regions
Gene Frequency
Population
Healthy Volunteers

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Kittles, R. A., Panguluri, R. K., Chen, W., Massac, A., Ahaghotu, C., Jackson, A., ... Dunston, G. M. (2001). CYP17 promoter variant associated with prostate cancer aggressiveness in African Americans. Cancer Epidemiology Biomarkers and Prevention, 10(9), 943-947.

CYP17 promoter variant associated with prostate cancer aggressiveness in African Americans. / Kittles, Rick A; Panguluri, R. K.; Chen, W.; Massac, A.; Ahaghotu, C.; Jackson, A.; Ukoli, F.; Adams-Campbell, L.; Isaacs, W.; Dunston, G. M.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 10, No. 9, 2001, p. 943-947.

Research output: Contribution to journalArticle

Kittles, RA, Panguluri, RK, Chen, W, Massac, A, Ahaghotu, C, Jackson, A, Ukoli, F, Adams-Campbell, L, Isaacs, W & Dunston, GM 2001, 'CYP17 promoter variant associated with prostate cancer aggressiveness in African Americans', Cancer Epidemiology Biomarkers and Prevention, vol. 10, no. 9, pp. 943-947.
Kittles, Rick A ; Panguluri, R. K. ; Chen, W. ; Massac, A. ; Ahaghotu, C. ; Jackson, A. ; Ukoli, F. ; Adams-Campbell, L. ; Isaacs, W. ; Dunston, G. M. / CYP17 promoter variant associated with prostate cancer aggressiveness in African Americans. In: Cancer Epidemiology Biomarkers and Prevention. 2001 ; Vol. 10, No. 9. pp. 943-947.
@article{b1861376faa24511b814ad3a7b0e54a9,
title = "CYP17 promoter variant associated with prostate cancer aggressiveness in African Americans",
abstract = "Androgens play an important role in the etiology of prostate cancer. The CYP17 gene encodes the cytochrome P450c17α enzyme, which is the rate-limiting enzyme in androgen biosynthesis. A T to C polymorphism in the 5′ promoter region has recently been associated with prostate cancer. However, contradictory data exists concerning the risk allele. To investigate further the involvement of the CYP17 variant with prostate cancer, we typed the polymorphism in three different populations and evaluated its association with prostate cancer and clinical presentation in African Americans. We genotyped the CYP17 polymorphism in Nigerian (n = 56), European-American (n = 74), and African-American (n = 111) healthy male volunteers, along with African-American men affected with prostate cancer (n = 71), using pyrosequencing. Genotype and allele frequencies did not differ significantly across the different control populations. African-American men with the CC CYP17 genotype had an increased risk of prostate cancer (odds ratio, 2.8; 95{\%} confidence interval, 1.0-7.4) compared with those with the TT genotype. A similar trend was observed between the homozygous variant genotype in African-American prostate cancer patients and clinical presentation. The CC genotype was significantly associated with higher grade and stage of prostate cancer (odds ratio, 7.1; 95{\%} confidence interval, 1.4-36,1). The risk did not differ significantly by family history or age. Our results suggest that the C allele of the CYP17 polymorphism is significantly associated with increased prostate cancer risk and clinically advanced disease in African Americans.",
author = "Kittles, {Rick A} and Panguluri, {R. K.} and W. Chen and A. Massac and C. Ahaghotu and A. Jackson and F. Ukoli and L. Adams-Campbell and W. Isaacs and Dunston, {G. M.}",
year = "2001",
language = "English (US)",
volume = "10",
pages = "943--947",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - CYP17 promoter variant associated with prostate cancer aggressiveness in African Americans

AU - Kittles, Rick A

AU - Panguluri, R. K.

AU - Chen, W.

AU - Massac, A.

AU - Ahaghotu, C.

AU - Jackson, A.

AU - Ukoli, F.

AU - Adams-Campbell, L.

AU - Isaacs, W.

AU - Dunston, G. M.

PY - 2001

Y1 - 2001

N2 - Androgens play an important role in the etiology of prostate cancer. The CYP17 gene encodes the cytochrome P450c17α enzyme, which is the rate-limiting enzyme in androgen biosynthesis. A T to C polymorphism in the 5′ promoter region has recently been associated with prostate cancer. However, contradictory data exists concerning the risk allele. To investigate further the involvement of the CYP17 variant with prostate cancer, we typed the polymorphism in three different populations and evaluated its association with prostate cancer and clinical presentation in African Americans. We genotyped the CYP17 polymorphism in Nigerian (n = 56), European-American (n = 74), and African-American (n = 111) healthy male volunteers, along with African-American men affected with prostate cancer (n = 71), using pyrosequencing. Genotype and allele frequencies did not differ significantly across the different control populations. African-American men with the CC CYP17 genotype had an increased risk of prostate cancer (odds ratio, 2.8; 95% confidence interval, 1.0-7.4) compared with those with the TT genotype. A similar trend was observed between the homozygous variant genotype in African-American prostate cancer patients and clinical presentation. The CC genotype was significantly associated with higher grade and stage of prostate cancer (odds ratio, 7.1; 95% confidence interval, 1.4-36,1). The risk did not differ significantly by family history or age. Our results suggest that the C allele of the CYP17 polymorphism is significantly associated with increased prostate cancer risk and clinically advanced disease in African Americans.

AB - Androgens play an important role in the etiology of prostate cancer. The CYP17 gene encodes the cytochrome P450c17α enzyme, which is the rate-limiting enzyme in androgen biosynthesis. A T to C polymorphism in the 5′ promoter region has recently been associated with prostate cancer. However, contradictory data exists concerning the risk allele. To investigate further the involvement of the CYP17 variant with prostate cancer, we typed the polymorphism in three different populations and evaluated its association with prostate cancer and clinical presentation in African Americans. We genotyped the CYP17 polymorphism in Nigerian (n = 56), European-American (n = 74), and African-American (n = 111) healthy male volunteers, along with African-American men affected with prostate cancer (n = 71), using pyrosequencing. Genotype and allele frequencies did not differ significantly across the different control populations. African-American men with the CC CYP17 genotype had an increased risk of prostate cancer (odds ratio, 2.8; 95% confidence interval, 1.0-7.4) compared with those with the TT genotype. A similar trend was observed between the homozygous variant genotype in African-American prostate cancer patients and clinical presentation. The CC genotype was significantly associated with higher grade and stage of prostate cancer (odds ratio, 7.1; 95% confidence interval, 1.4-36,1). The risk did not differ significantly by family history or age. Our results suggest that the C allele of the CYP17 polymorphism is significantly associated with increased prostate cancer risk and clinically advanced disease in African Americans.

UR - http://www.scopus.com/inward/record.url?scp=0034852595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034852595&partnerID=8YFLogxK

M3 - Article

C2 - 11535545

AN - SCOPUS:0034852595

VL - 10

SP - 943

EP - 947

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 9

ER -